Furthermore, using PD-1/PD-L1 inhibitors as second- or third-line therapy improved the overall survival (OS), when compared to standard chemotherapy in KRAS-mutant NSCLC patients5,8,9,17. Here, KRAS is linked to non-small cell lung carcinoma.